An interventional study of Corsano CardioWatch and Prehab4Cancer Programme in Pancreatic Cancer, Pancreatic Neoplasms and Periampullary Carcinoma, sponsored by Manchester University NHS Foundation Trust. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by Manchester University NHS Foundation Trust · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to evaluate whether a wearable-enabled prehabilitation and rehabilitation pathway can improve recovery and post-operative outcomes in adults undergoing surgery for pancreatic cancer or related pancreatic/periampullary conditions.
The main questions it aims to answer are:
Does a wearable-enabled prehabilitation and rehabilitation programme reduce post-operative complications within 30 and 90 days after surgery? Is the use of wearable devices and remote monitoring feasible, acceptable, and useful for patients and healthcare professionals during the perioperative pathway?
Researchers will compare patients receiving the wearable-enabled pathway with a matched historical control group who received standard care to determine whether the intervention is associated with improved surgical and recovery outcomes.
Participants will:
Provide informed consent and complete baseline assessments and questionnaires. Take part in the Greater Manchester Prehab4Cancer programme before surgery, including personalised exercise, nutritional support, and wellbeing support.
Wear a Corsano CardioWatch device to continuously monitor physiological and activity data.
Use home monitoring equipment, including weight scales and blood pressure monitoring devices.
Complete questionnaires and participant logs during prehabilitation and recovery.
Receive regular support from the research team during participation. Undergo pancreatic surgery and receive standard NHS perioperative care. Continue wearable monitoring and rehabilitation after hospital discharge. Be followed for up to 12 months after surgery using routine clinical data to assess recovery, complications, hospital utilisation, and survival.
Optionally participate in a focus group to discuss their experiences of wearable-enabled care.
POWR-PaC (Perioperative Optimisation and Wearable Remote monitoring of Pancreatic Cancer) is a prospective, single-centre study evaluating the integration of wearable technologies into an established perioperative prehabilitation and rehabilitation pathway for patients undergoing pancreatic surgery. The study is being conducted at Manchester University NHS Foundation Trust in partnership with the Greater Manchester Prehab4Cancer programme.
Major pancreatic surgery is associated with substantial morbidity, prolonged recovery, and significant variation in patient outcomes. Although prehabilitation programmes have demonstrated benefits for physical fitness and surgical preparedness, there is limited evidence regarding the role of continuous physiological monitoring and remote assessment throughout the perioperative pathway. Wearable technologies may provide objective, longitudinal measures of activity, sleep, cardiovascular function, recovery trajectories, and treatment tolerance that are not routinely captured during standard care.
Participants enrolled in the intervention arm will be prescribed the targeted Greater Manchester Prehab4Cancer pathway and will additionally receive a wearable monitoring package consisting of a Corsano CardioWatch device and supporting home monitoring equipment. Physiological and behavioural measures collected by the wearable system may include physical activity, heart rate, respiratory rate, oxygen saturation, skin temperature, sleep-related metrics, and other device-derived indicators. Weight and blood pressure measurements will also be collected using home monitoring equipment where applicable.
Data collection will occur across the perioperative pathway, including the pre-operative prehabilitation period, inpatient surgical admission, and post-operative rehabilitation phase. Clinical, functional, physiological, and patient-reported outcome measures will be collected alongside routinely recorded healthcare data. The study will evaluate data completeness, participant adherence, acceptability of remote monitoring, and the potential relationship between wearable-derived metrics and clinical outcomes.
A matched historical control cohort will be identified from electronic health records at Manchester University NHS Foundation Trust. Control participants will have undergone pancreatic surgery and standard perioperative care without participation in the wearable-enabled pathway. Matching methods will be used to minimise baseline differences between groups and support comparative analyses of clinical outcomes.
The primary clinical evaluation will focus on post-operative morbidity within 30 and 90 days of surgery. Secondary analyses will assess measures including mortality, hospital utilisation, days alive and out of hospital, functional recovery, quality of life, and engagement with prehabilitation and rehabilitation services. Exploratory analyses will investigate whether longitudinal wearable data can provide early indicators of recovery status, post-operative complications, or treatment response.
The study also incorporates a mixed-methods evaluation of implementation. Participants, healthcare professionals, and exercise specialists may be invited to take part in qualitative focus groups to explore experiences of wearable-supported care, barriers and facilitators to adoption, usability of the technology, and opportunities for future pathway optimisation. Qualitative findings will be used to inform the future design, implementation, and scale-up of digitally enabled perioperative pathways within NHS surgical services.
The findings from POWR-PaC will provide evidence regarding the feasibility, acceptability, and potential clinical value of integrating wearable technologies into perioperative cancer care and will inform the development of larger effectiveness studies and future digitally enabled surgical pathways.
3,896 studies on the registry are indexed under Pancreatic Neoplasms; 1,007 are open to participants now.
This study's planned enrollment of 120 is above the median of 47 across 2,932 interventional studies indexed under Pancreatic Neoplasms.
Browse Pancreatic Neoplasms studies →Manchester University NHS Foundation Trust is the lead sponsor of 140 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Pancreatic cancer Distal cholangiocarcinoma Ampullary carcinoma Duodenal carcinoma Premalignant pancreatic lesions, including Intraductal Papillary Mucinous Neoplasms (IPMNs).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants undergoing pancreatic surgery will receive the Greater Manchester Prehab4Cancer programme supported by wearable monitoring, home physiological monitoring, and remote follow-up throughout the perioperative pathway. Outcomes will be compared with a propensity-score-matched historical cohort identified from routine electronic health records.
Device: Corsano CardioWatch · Behavioral: Prehab4Cancer Programme
Historical patients who underwent pancreatic surgery and received standard perioperative care without wearable monitoring. Participants will be identified retrospectively from electronic health records and matched to intervention participants using propensity score methods based on demographic and clinical characteristics. No study intervention will be delivered.
A wearable monitoring device used throughout the perioperative pathway to collect continuous physiological and activity data, including measures such as physical activity, heart rate, respiratory rate, oxygen saturation, skin temperature, and sleep-related metrics.
A personalised prehabilitation and rehabilitation programme comprising exercise, nutritional support, and wellbeing support delivered before and after pancreatic surgery.
Post-operative complications
Occurrence of post-operative complications following pancreatic surgery.
Time frame: 30 and 90 days post-surgery
All-cause mortality
All-cause mortality post-surgery
Time frame: 30, 90, 365 days post-surgery.
Days Alive and Out of Hospital (DAOH)
Number of days participants are alive and not admitted to hospital during the preoperative period (from enrolment to surgery) and during the postoperative recovery period. DAOH incorporates mortality, length of stay, and hospital readmissions into a single patient-centred outcome measure.
Time frame: From enrolment to date of surgery (preoperative period); and from date of surgery to 30, 90, and 365 days post-operatively (postoperative period).
Length of Stay
Number of days spent in hospital during the index surgical admission following pancreatic resection.
Time frame: From date of surgical resection to date of discharge from the index hospital admission, assessed up to 90 days post-surgery.
Completeness of Wearable Data Collected via Corsano CardioWatch
Percentage of expected physiological and activity data points (heart rate, SpO2, activity, sleep) successfully captured and transmitted, relative to the total expected monitoring period. Unit: percentage
Time frame: From enrolment until completion of the rehabilitation programme, up to 12 months post-surgery.
Participant Adherence to Wearable Device Wear Time
Percentage of prescribed daily wear/use time achieved by participants. Unit: percentage
Time frame: From enrolment until completion of the rehabilitation programme, up to 12 months post-surgery.
Technical Feasibility of Wearable Device Data Collection
Number of technical issues (device malfunction, connectivity failure, data transmission gaps) encountered with the Corsano CardioWatch. Unit: count
Time frame: From enrolment until completion of the rehabilitation programme, up to 12 months post-surgery.
No study locations are listed for this record.
Plan to share: Yes — Individual participant data underlying the results reported in publications arising from this study may be shared in an anonymised form following completion of the study and publication of the primary results. Shared datasets may include demographic data, clinical characteristics, patient-reported outcome measures, wearable-derived physiological and activity data, and key outcome variables relevant to the published analyses. Data will be fully anonymised prior to sharing and no directly identifiable information will be released. Access will be subject to approval by Manchester University NHS Foundation Trust, compliance with applicable data sharing agreements, participant consent, UK GDPR, research governance requirements, and any relevant ethical approvals. Supporting documentation, including the study protocol, statistical analysis methods, and data dictionary, may also be made available where appropriate.
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Individual participant data (IPD) will become available following publication of the primary study results and completion of the final study report. Data are expected to be available beginning approximately 6 to 12 months after publication of the primary study findings. Anonymised participant-level datasets and supporting documentation may remain available for up to 10 years following study completion, in accordance with the study protocol and Manchester University NHS Foundation Trust data retention policies. Data sharing will be subject to appropriate governance approvals, data-sharing agreements, and applicable legal and regulatory requirements. Supporting materials, including the study protocol, data dictionary, and statistical analysis methods, may also be made available during this period.
Access criteria: Anonymised individual participant data (IPD) and supporting documentation may be made available to researchers following publication of the primary study results. Data that may be shared include demographic variables, clinical outcomes, patient-reported outcome measures, and wearable-derived physiological and activity data relevant to the published analyses. Access requests must be methodologically sound and for scientifically valid research purposes. Requests will be reviewed by the Chief Investigator and Manchester University NHS Foundation Trust in accordance with participant consent, applicable ethics approvals, data protection legislation, and data-sharing agreements. Data will only be released in a fully anonymised form and through secure data-sharing mechanisms. Supporting documents, including the study protocol, data dictionary, and statistical analysis methods, may also be made available where appropriate.
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Mar 2028, 17 months later.
Of 403 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 17 months is below that.
Counting every sponsor, half of 430 studies reached it within 44 months; a quarter within 26 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Manchester University NHS Foundation Trust →